

NEURO

AbbVie RTOG 3508/ M13-813: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 (anti-EGFR (epidermal growth factor receptor) monoclonal (mAb) antibody drug conjugate or ADC) with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence 1)

<https://clinicaltrials.gov/ct2/show/NCT02573324?term=M13-813&rank=1>

